Drug Profile

Research programme: immune checkpoint anticancer therapies - Takeda/Symphogen

Alternative Names: Immune checkpoint therapies - Takeda/Symphogen

Latest Information Update: 09 Jun 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Baxalta; Symphogen
Developer Symphogen; Takeda
Class Antineoplastics; Immunotherapies
Mechanism of Action Checkpoint kinase inhibitors; Immune checkpoint protein inhibitors; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Jun 2020 Symphogen has been acquired by Servier
28 Feb 2020 No recent reports of development identified for research development in Cancer in Denmark
08 Jan 2019 Shire has been acquired and merged into Takeda

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com